Indivior (INDV) AI Stock Analysis

• Market Cap: $4.55B
• Dividend Yield: N/A
• Average Volume (3M): 2.95M
• Price to Earnings (P/E): 36.2
• Beta (1Y): 0.66
• Revenue Growth: -0.25%
• EPS Growth: N/A
• Country: US
• Employees: 1,030
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.72
• Shares Outstanding: 124,853,900
• 10 Day Avg. Volume: 5,009,490
• 30 Day Avg. Volume: 2,946,542
• PEG Ratio: 239.55
• Price to Book (P/B): -4.71
• Price to Sales (P/S): 1.38
• P/FCF Ratio: 234.39
• Enterprise Value/Market Cap: 0.58
• Enterprise Value/Revenue: 2.22
• Enterprise Value/Gross Profit: 2.68
• Enterprise Value/Ebitda: 8.32
• 1Y Price Target: $38.00
• Price Target Upside: 4.54% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 2.34
• Revenue Forecast (FY): $1.19B

• Rating: 66 Neutral
• Price Target: $39.00 ▲(7.29% Upside)

Indivior's overall stock score is driven by strong technical momentum and positive earnings call sentiment, despite financial instability and high valuation concerns. The company's strategic initiatives and raised guidance contribute positively, but financial risks and valuation limit the score.

Positive Factors

Revenue Growth

The increase in revenue, driven by SUBLOCADE's performance, indicates strong market demand and effective product positioning, supporting long-term growth.

Cost Reduction Initiatives

Significant cost savings will enhance profitability and operational efficiency, providing a more sustainable financial structure over the long term.

Strategic Redomiciliation

Redomiciliation to the U.S. aligns Indivior with key markets and stakeholders, potentially improving market access and regulatory alignment.

Negative Factors

Negative Equity

Negative equity indicates financial instability, which can limit the company's ability to invest in growth opportunities and manage debt.

Organizational Restructuring Costs

High restructuring costs can strain financial resources and may impact short-term profitability, affecting long-term financial health.

Limited LAI Market Growth

Limited growth in the LAI market suggests challenges in expanding market share for SUBLOCADE, potentially affecting future revenue growth.

Indivior Business Overview & Revenue Model

Company Description

Indivior PLC is a global pharmaceutical company focused on the treatment of opioid use disorder and other addiction-related conditions. The company operates primarily in the healthcare sector and is best known for its core product, Suboxone, a combination of buprenorphine and naloxone, which is used to help individuals reduce their dependence on opioids. Indivior develops and commercializes innovative therapies aimed at addressing the complex challenges of addiction and has a commitment to improving patient outcomes through its specialized treatment solutions.

How the Company Makes Money

Indivior generates revenue primarily through the sale of its pharmaceutical products, with Suboxone being its flagship product, contributing a significant portion of its sales. The company operates on a revenue model that includes direct sales to healthcare providers and pharmacies, as well as partnerships with healthcare organizations and distributors. Additionally, Indivior has engaged in licensing agreements and collaborations that provide further revenue streams. The company also invests in research and development to expand its product portfolio, aiming to introduce new therapies that target addiction and related disorders, which can enhance its earnings potential over time.

Indivior Financial Statement Overview

Summary

Indivior shows strong revenue growth and improving profitability, with a robust gross profit margin and net profit margin improvement. However, the balance sheet is concerning due to negative equity and high leverage, and cash flow management is mixed with declining free cash flow growth.

Income Statement

Indivior's income statement shows a strong gross profit margin of 82.8% TTM, indicating efficient cost management. The net profit margin improved significantly to 14.1% TTM from near breakeven levels in previous years, reflecting enhanced profitability. Revenue growth is robust at 59.6% TTM, showcasing strong sales momentum. However, EBIT and EBITDA margins, while improved, still suggest room for operational efficiency gains.

Balance Sheet

The balance sheet reveals a concerning negative stockholders' equity, leading to a negative debt-to-equity ratio. This indicates potential financial instability and high leverage risk. Return on equity is negative, highlighting challenges in generating returns for shareholders. The equity ratio is also negative, suggesting a reliance on debt financing.

Cash Flow

Cash flow analysis shows a decline in free cash flow growth by 30.7% TTM, indicating potential liquidity issues. However, the operating cash flow to net income ratio improved to 0.20 TTM, suggesting better cash conversion. The free cash flow to net income ratio of 0.69 TTM indicates a reasonable level of cash generation relative to profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.18B	1.19B	1.09B	901.00M	791.00M	647.00M
Gross Profit	978.00M	957.00M	919.00M	750.00M	664.00M	550.00M
EBITDA	315.00M	84.00M	-99.00M	-46.00M	238.00M	-123.00M
Net Income	166.00M	2.00M	-129.00M	-44.00M	205.00M	-148.00M
Balance Sheet
Total Assets	1.42B	1.32B	1.76B	1.78B	1.83B	1.53B
Cash, Cash Equivalents and Short-Term Investments	445.00M	320.00M	410.00M	897.83M	1.10B	858.00M
Total Debt	356.00M	375.00M	283.00M	277.00M	286.00M	285.00M
Total Liabilities	1.62B	1.67B	1.96B	1.73B	1.63B	1.45B
Stockholders Equity	-207.00M	-348.00M	-191.00M	51.28M	203.00M	82.00M
Cash Flow
Free Cash Flow	134.49M	7.00M	-353.00M	-9.00M	319.00M	-197.00M
Operating Cash Flow	193.43M	36.00M	-300.00M	-4.00M	353.00M	-193.00M
Investing Cash Flow	-35.01M	69.00M	-95.00M	-222.00M	-14.00M	-4.00M
Financing Cash Flow	4.44M	-102.00M	-64.00M	-101.00M	-94.00M	-10.00M

Indivior Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 36.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INDV, the sentiment is Positive. The current price of 36.35 is above the 20-day moving average (MA) of 35.05, above the 50-day MA of 31.23, and above the 200-day MA of 19.91, indicating a bullish trend. The MACD of 1.34 indicates Positive momentum. The RSI at 67.95 is Neutral, neither overbought nor oversold. The STOCH value of 62.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INDV.

Indivior Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	77 Outperform	$1.26B	11.73	14.84%	―	-0.03%	-27.66%
PCRX	69 Neutral	$1.12B	57.70	2.90%	―	3.14%	―
INDV	66 Neutral	$4.55B	36.19	―	―	-0.25%	―
ANIP	64 Neutral	$1.81B	49.51	7.83%	―	48.87%	―
SUPN	55 Neutral	$2.95B	-151.73	-1.86%	―	4.54%	-130.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVO	46 Neutral	$1.10B	-6.32	-17.46%	―	-1.19%	5.06%

Indivior Corporate Events

Indivior Added to S&P SmallCap 600, Enhancing Visibility

On December 22, 2025, Indivior PLC announced that its ordinary shares were included in the S&P SmallCap 600 index, aligning its capital markets profile more closely with its U.S.-focused business and signaling that it meets key criteria for liquidity and financial viability in the small-cap segment. Management highlighted the move as a significant milestone that supports its strategy to grow SUBLOCADE, its leading long-acting injectable treatment for moderate to severe opioid use disorder, under a simplified operating model, which could enhance visibility among investors and potentially bolster its competitive position in the addiction-treatment market.

Indivior approves executive salary increases for senior leadership

On December 12, 2025, Indivior PLC’s board approved base salary increases for its top executives, effective January 1, 2026, following a competitive market review and recommendations from its Compensation Committee and external consultants. Chief Executive Officer Joseph Ciaffoni’s annual base salary will rise from $1,050,000 to $1,115,000, while Chief Financial Officer Ryan Preblick’s base pay will increase from $559,000 to $604,000, signaling the company’s intention to retain and reward senior leadership amid ongoing market pressures in the pharmaceutical sector.

Indivior Shareholders Approve Scheme of Arrangement

On December 11, 2025, Indivior PLC shareholders approved amended articles of association to facilitate a scheme of arrangement. This scheme ensures that Indivior PLC becomes a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc. The approval process included two shareholder meetings, with resolutions passed to authorize necessary actions for the scheme’s implementation. The scheme’s completion is pending a court sanction expected in January 2026.

Indivior Concludes DOJ Settlement with Final Payment

On November 20, 2025, Indivior PLC announced the conclusion of its legacy matter with the U.S. Department of Justice by paying the remaining $295 million obligation. This payment, funded from the company’s cash reserves, terminates the resolution agreement with the DOJ, removing a significant liability and simplifying Indivior’s capital structure.

Indivior Plans Re-domicile to Delaware by December

On November 14, 2025, Indivior PLC announced its plan to re-domicile from the U.K. to Delaware, a move that will be voted on by shareholders at an Extraordinary General Meeting on December 11, 2025. This strategic shift is aimed at establishing Indivior Pharmaceuticals, Inc. as the new holding company for the Indivior Group, potentially impacting its operational framework and market positioning.

Indivior Raises 2025 Guidance Amid Strategic Moves

Indivior reported its third-quarter 2025 financial results, showing a 2% year-over-year increase in total net revenue to $314 million, driven by a 15% rise in SUBLOCADE’s net revenue. The company has raised its full-year 2025 financial guidance, expecting significant growth in adjusted EBITDA. Indivior is optimizing its Rest of World business by exiting several non-U.S. markets and plans to redomicile in the U.S. These strategic moves are expected to generate substantial operating expense savings and improve cash generation starting in 2026.

Indivior Announces Redomiciliation to U.S. from U.K.

On October 1, 2025, Indivior PLC announced its intention to redomicile from the U.K. to the U.S. by establishing a new parent company, Indivior Pharmaceuticals, Inc., in Delaware. This strategic move follows its Nasdaq listing and aims to enhance its U.S. capital market presence, simplify governance, and align with U.S. health policy stakeholders. The redomiciliation process involves a U.K. court-sanctioned scheme of arrangement and requires shareholder approval, with the transition expected to be completed by late January 2026. This change is anticipated to position Indivior as a U.S.-based treatment innovator, facilitating collaboration on advancing its opioid use disorder treatment, SUBLOCADE®.